An In Depth Study Evaluating The Experiences of Patients In Schizophrenia Research
Study Details
Study Description
Brief Summary
Historically, research participation has been biased toward certain demographics. However, there is a shortage of studies that delve into the underlying factors that influence patient participation, both positively and negatively.
Several people will be invited to enroll in this study so that it may collect a variety of data about schizophrenia clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.
The data collected from this study will be analyzed and used to improve the experiences of future schizophrenia patients who are recruited for medical trials.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Number of patients who decide to participate in a schizophrenia research [3 months]
- Rate of patients who remain in schizophrenia clinical trial to trial completion [12 month]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient has self-identified as planning to enroll in a clinical trial
-
Patient has been diagnosed with schizophrenia
-
Patient is a minimum of 18 years or older
Exclusion Criteria:
-
Patient does not understand, sign, and return consent form
-
Inability to perform regular electronic reporting
-
Patient is pregnant
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Power Life Sciences Inc.
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Study Documents (Full-Text)
More Information
Publications
- Barnett PG, Scott JY, Rosenheck RA; CSP 555 Study Group. How do clinical trial participants compare to other patients with schizophrenia? Schizophr Res. 2011 Aug;130(1-3):34-9. doi: 10.1016/j.schres.2011.03.033. Epub 2011 Apr 22.
- Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014 Jan;40(1):192-213. doi: 10.1093/schbul/sbs150. Epub 2012 Dec 17.
- Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C. Improving Current Treatments for Schizophrenia. Drug Dev Res. 2016 Nov;77(7):357-367. doi: 10.1002/ddr.21337. Epub 2016 Sep 16.
- 84771018